
News|Articles|June 11, 2026
Advancing the Field: Stem Cell Therapies and the Future of Parkinson Disease Treatment
Author(s)Marco Meglio
Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.
Advertisement
Advertisement
In a recently launched special NeurologyLive® Roundtable Discussion developed in collaboration with the International Society for Stem Cell Research (ISSCR), two leading Parkinson disease experts explored the rapidly advancing field of stem cell medicine and its potential role in treating Parkinson disease.
Related to this article

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.
Advertisement
Advertisement



